Emerging treatment options for recurrent ovarian cancer: The potential role of olaparib

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 1197-1206

  Shaw, Heather M ^a   Hall, Marcia ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

Anticancer; Polymerase inhibitor

Indexed keywords

BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; BUPARLISIB; CARBOPLATIN; CEDIRANIB; CISPLATIN; DACARBAZINE; DOXORUBICIN; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLAPARIB; PACLITAXEL; PLACEBO; TOPOTECAN;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SCREENING; FATIGUE; GENE MUTATION; HUMAN; NAUSEA; NONHUMAN; OVARY CANCER; OVARY TUMOR; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; REVIEW; TASTE DISORDER; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 84884125515     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S30748     Document Type: Review

References (69)

1. Cancer Research UK. Cancer mortality for common cancers [webpage on the Internet]. London, UK: Cancer Research UK; 2011. Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/mortality/cancerdeaths. Accessed October 10, 2012.
2. Cancer Research UK. Ovarian cancer survival statistics [webpage on the Internet]. London, UK: Cancer Research UK; 2012. Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/survival. Accessed October 10, 2012.
3. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460(3):237-249.
4. National Cancer Institute. SEER stat fact sheets: ovary [webpage on the Internet]. Bethesda, MD; 2010. National Cancer Institute. Available from: http://seer.cancer.gov/statfacts/html/ovary.html#prevalence. Accessed October 10, 2012.
5. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117-1130.
6. Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30(21):2654-2663.
7. Pennington KP, Swisher EM. Hereditary ovarian cancer: beyond the usual suspects. Gynecol Oncol. 2012;124(2):347-353.
8. Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS, Casado A. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. Eur J Cancer. 2011;47 Suppl 3:S88-S92.
9. Colombo N, Peiretti M, Parma G, et al; for the ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v23-v30.
10. Perren TJ, Swart AM, Pfisterer J, et al; for the ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011; 365(26):2484-2496.
11. Burger RA, Brady MF, Bookman MA, et al; for the Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473-2483.
12. Kristensen G, Perren T, Qian W et al. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomised trial of bevacizumab in women with newly diagnosed ovarian cancer. Presented at: American Society of Clinical Oncology; June, 4-8; 2011; Chicago, IL, USA. Abstract LBA 5006.
13. Parmar MK, Ledermann JA, Colombo N, et al; for the ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361(9375):2099-2106.
14. Pfisterer J, Plante M, Vergote I, et al; for the AGO-OVAR; NCIC CTG; EORTC GCG. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29):4699-4707.
15. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039-2045.
16. Hall M, Rustin G. Recurrent ovarian cancer: when and how to treat. Curr Oncol Rep. 2011;13(6):459-471.
17. Weroha SJ, Oberg AL, Ziegler KL, et al. Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecol Oncol. 2011; 122(1):116-120.
18. Garcia AA, Sill MW, Lankes HA, et al. A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2012;124(3):569-574.
19. Karp DD, Pollak MN, Cohen RB, et al. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol. 2009;4(11):1397-1403.
20. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379(9829):1893-1901.
21. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852-861.
22. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66-71.
23. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789-792.
24. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer. 2004;4(10):814-819.
25. Wysham WZ, Mhawech-Fauceglia P, Li H, et al. BRCAness profile of sporadic ovarian cancer predicts disease recurrence. PLoS One. 2012;7(1):e30042.
26. Rigakos G, Razis E. BRCAness: finding the Achilles heel in ovarian cancer. Oncologist. 2012;17(7):956-962.
27. Kim H, D'Andrea AD. Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev. 2012;26(13): 1393-1408.
28. Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer. 2008;8:17.
29. Hennessy BT, Timms KM, Carey MS, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010;28(22):3570-3576.
30. Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer. 2012;12(9):587-598.
31. Chapman JR, Taylor MR, Boulton SJ. Playing the end game: DNA double-strand break repair pathway choice. Mol Cell. 2012;47(4):497-510.
32. De Vos M, Schreiber V, Dantzer F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol. 2012;84(2):137-146.
33. Menear KA, Adcock C, Boulter R, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 2008;51(20):6581-6591.
34. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011;5(4):387-393.
35. Iglehart JD, Silver DP. Synthetic lethality a new direction in cancerdrug development. N Engl J Med. 2009;361(2):189-191.
36. Gottipati P, Vischioni B, Schultz N, et al. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res. 2010;70(13):5389-5398.
37. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035):917-921.
38. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913-917.
39. Kortmann U, McAlpine JN, Xue H, et al. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin Cancer Res. 2011;17(4):783-791.
40. Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A. 2008;105(44):17079-17084.
41. Evers B, Drost R, Schut E, et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res. 2008;14(12):3916-3925.
42. National Cancer Institute. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events [webpage on the Internet]. Bethesda, MD: National Cancer Institute; 2012. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed October 19, 2012.
43. Rustin GJ, Quinn M, Thigpen T, et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst. 2004;96(6):487-488.
44. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123-134.
45. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28(15): 2512-2519.
46. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 muta-tions and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245-251.
47. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19(14):3312-3322.
48. Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30(4):372-379.
49. Graeser M, McCarthy A, Lord CJ, et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res. 2010;16(24): 6159-6168.
50. Konstantinopoulos PA, Spentzos D, Karlan BY, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010;28(22):3555-3561.
51. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382-1392.
52. Carlson RH. Ovarian cancer: future of PARP inhibitor olaparib still uncertain in platinum-sensitive serous disease. Oncology Times. 2012; 34(19):37-38.
53. Khan OA, Gore M, Lorigan P, et al. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer. 2011;104(5): 750-755.
54. Samol J, Ranson M, Scott E, et al. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Invest New rugs. 2012;30(4): 1493-1500.
55. Dean E, Middleton MR, Pwint T, et al. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer. 2012;106(3): 468-474.
56. Rajan A, Carter CA, Kelly RJ, et al. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res. 2012;18(8):2344-2351.
57. National Cancer Institute. Olaparib and carboplatin to treat breast and ovarian cancer. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01445418?term=olaparib&rank=37. Accessed October 24, 2012.
58. ClinicalTrials.gov. Olaparib in combination with carboplatin for refractory or recurrent women's cancers [webpage on the Internet]. Bethesda, MD: US National Institutes of Health; 2011. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01237067. Accessed October 24, 2012.
59. ClinicalTrials.gov. Study to assess the safety and tolerability of a PARP inhibitor in combination with carboplatin and/or paclitaxel [webpage on the Internet]. Bethesda, MD: US National Institutes of Health; 2011. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00516724?term=olaparib& rank=19. Accessed October 24, 2012.
60. ClinicalTrials.gov. Study to compare the efficacy and safety of olaparib when given in combination with carboplatin and paclitaxel, compared with carboplatin and paclitaxel in patients with advanced ovarian cancer [webpage on the Internet]. Bethesda, MD: US National Institutes of Health; 2011. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01081951?term=olaparib&rank=15. Accessed October 24, 2012.
61. ClinicalTrials.gov. Phase Ib study of olaparib plus weekly carboplatin and paclitaxel in relapsed ovarian cancer [webpage on the Internet]. Bethesda, MD: US National Institutes of Health; 2011. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01650376?term=olaparib&rank=11. Accessed October 24, 2012.
62. ClinicalTrials.gov. Phase I of BKM120/olaparib for triple negative breast cancer or high grade serous ovarian cancer [webpage on the Internet]. Bethesda, MD: US National Institutes of Health; 2011. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01623349?term=olaparib&rank=2. Accessed October 24, 2012.
63. ClinicalTrials.gov. Cediranib and olaparib in combination for recurrent ovarian or triple-negative breast cancer [webpage on the Internet]. Bethesda, MD: US National Institutes of Health; 2011. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01116648?term=olaparib&rank=1. Accessed October 24, 2012.
64. Barber LJ, Sandhu S, Chen L, et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol. 2013; 229(3):422-429.
65. Jaspers JE, Kersbergen A, Boon U, et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 2013;3(1):68-81.
66. Oplustilova L, Wolanin K, Mistrik M, et al. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle. 2012;11(20):3837-3850.
67. Mukhopadhyay A, Plummer ER, Elattar A, et al. Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival. Cancer Res. 2012;72(22):5675-5682.
68. Nowsheen S, Bonner JA, Yang ES. The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy. Radiother Oncol. 2011;99(3):331-338.
69. Redon CE, Nakamura AJ, Zhang YW, et al. Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res. 2010;16(18):4532-4542.